A Two-part Randomized, Double-blind Placebo Controlled Trial to Assess the Safety and Tolerability of Single and Repeat Ascending Intranasal Doses of RIG-101 in Healthy Participants Followed by Repeat Daily Administration in Adult Participants With Asthma [Part A] Followed by a Randomized Double-blind Placebo Controlled Part to Assess the Efficacy and Safety of RIG-101 in Adult Participants With Asthma Before and After Viral Challenge With Human Rhinovirus RV-A16 [Part B].
Latest Information Update: 27 Mar 2026
At a glance
- Drugs RIG 101 (Primary)
- Indications Asthma; Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors RIGImmune
Most Recent Events
- 27 Mar 2026 New trial record